Pulpotomy, which belongs to vital pulp therapy, has become a strategy for managing pulpitis in recent decades. This minimally invasive treatment reflects the recognition of preserving healthy dental pulp and optimizing long-term patient-centered outcomes. Pulpotomy is categorized into partial pulpotomy (PP), the removal of a partial segment of the coronal pulp tissue, and full pulpotomy (FP), the removal of whole coronal pulp, which is followed by applying the biomaterials onto the remaining pulp tissue and ultimately restoring the tooth. Procedural decisions for the amount of pulp tissue removal or retention depend on the diagnostic of pulp vitality, the overall treatment plan, the patient's general health status, and pulp inflammation reassessment during operation. This statement represents the consensus of an expert committee convened by the Society of Cariology and Endodontics, Chinese Stomatological Association. It addresses the current evidence to support the application of pulpotomy as a potential alternative to root canal treatment (RCT) on mature permanent teeth with pulpitis from a biological basis, the development of capping biomaterial, and the diagnostic considerations to evidence-based medicine. This expert statement intends to provide a clinical protocol of pulpotomy, which facilitates practitioners in choosing the optimal procedure and increasing their confidence in this rapidly evolving field.
Humans ; Calcium Compounds/therapeutic use* ; Consensus ; Dental Pulp ; Dentition, Permanent ; Oxides/therapeutic use* ; Pulpitis/therapy* ; Pulpotomy/standards*

Objective To analyze the efficacy of different nucleoside(acid)analogs(NAs)used as monotherapy and in combination with pegylated interferon α-2b(Peg-IFN-α-2b)in the treatment of chronic hepatitis B(CHB).Methods A retrospective analysis was conducted on 229 CHB patients who visited the Hepatology Department of the Third People's Hospital of Kunming from September 2022 to August 2023.Patients were divided into six groups based on their antiviral regimen:entecavir(ETV)group(A,n=47),ETV combined with Peg-IFN-α-2b group(B,n=19),Tenofovir Alafenamide(TMF)group(C,n=64),TMF combined with Peg-IFN-α-2b group(D,n=35),Tenofovir Disoproxil Fumarate(TDF)group(E,n=29),and TDF combined with Peg-IFN-α-2b group(F,n=35).The blood routine,liver function,kidney function,HBV serological markers,and HBV-DNA levels were compared before and after 24 weeks of treatment.Results After 24 weeks of treatment,there were no statistically significant differences in efficacy rates and HBV-DNA positivity rates between the monotherapy with NAs and the combination with Peg-IFN-α-2b(P>0.05).Comparing before and after treatment,the ETV group had the highest effective rate,while TDF combined with Peg-IFN-α-2b group had the lowest effective rate.TDF group had the highest efficiency,while ETV combined with Peg-IFN-α-2b group had the lowest efficiency.Except for ETV+Peg-IFN-α-2b and TDF+Peg-IFN-α-2b groups,the HBV-DNA positivity rates in the other four groups were significantly lower after treatment compared to before(P<0.05).There was a significant difference in HBsAg levels among the different treatment regimens of monotherapy with NAs and combination with Peg-IFN-α-2b(P=0.0483).Additionally,except for the ETV and TDF groups,the serum HBsAg levels in the other four groups were significantly lower after treatment compared to before(P<0.05).There were no significant difference in LSM and GFR before and after treatment(P>0.05).In the monotherapy groups,ALT and GGT levels were significantly lower after treatment compared to before(P<0.05),while in the combination Peg-IFN-α-2b group,WBC,NEUT,and PLT levels were significantly lower after treatment compared to before(P<0.05).Conclusion Combination therapy with Peg-IFN-α-2b can reduce HBsAg levels and may be more effective in controlling the virus;however,it may cause adverse reactions such as bone marrow suppression,increasing risks.Physicians and patients need to weigh the benefits against the risks and develop personalized treatment plans based on individual circumstances.

Objective:In order to further enrich and improve the pricing strategy of chronic disease health management services in China.Methods:A discrete choice test was used to investigate the willingness to pay for personalized health service packages for chronic disease patients in Wuhou District,Chengdu City,as a representative of personalized health service packages for primary healthcare institutions,with integration as a utility indicator and blood pressure/glucose control rate as an effect indicator,which was used as a basis for pricing.Results:A total of 238 valid questionnaires were considered.According to conditional logit regression analysis,respondents were willing to pay 147.13 yuan/year to improve service package integration from low to high,and 177.12 yuan/year to improve blood pressure/blood sugar from one day a week(low level)to seven days a week(high level),but there was no significant willingness to pay for other improvements.Conclusion:It is discovered that there is a comparable willingness to pay for health management services to patients with chronic diseases in Chinese community in terms of service utility and effect,and it is proposed that the value of service experience be included in primary health management pricing.

Objective:To explore the difficulties and methods of value-based pricing of healthcare services,and to provide references for the price management of healthcare services in China.Methods:Based on the analysis of literature and policy,the operational methods of value-based pricing are clarified,and the international application experience of value-based pricing is reviewed.Comprehensive field research and interviews are conducted to analyze the difficulties in applying value-based pricing to healthcare services.Results:Currently,there are no mature theories and methods for value-based pricing of healthcare services,and there are also many practical difficulties in financing,payment,assessment and evaluation policies.Conclusion:In the future,it should consider incorporating service experience into the value framework independently of utility,and take"service utility"as the basis for pricing healthcare services,and select relevant indicators for measurement.At the same time,the price of healthcare services should take into account the willingness to pay of multiple parties,and stakeholders need to work closely together to form a consensus on value.

Objective:Compared to pricing based on input value,pricing based on output can better motivate service outcomes towards expectations and enhance input-output efficiency.The path of outcome value-oriented pricing for healthcare services is explored to provide a theoretical foundation for the value-based pricing of healthcare services.Methods:The concepts,methods and international experience of value pricing are sorted out.Results:Outcome-based pricing in healthcare services is divided into effect and utility,and is classified into four categories based on the different emphasis on the effect and utility of healthcare services.Conclusion:Services with a strong emphasis on effectiveness can draw inspiration from the Quantified Quality of Life(QALY)results in the medical technology field,while services with a strong emphasis on utility may require the development of new utility scales for service evaluation.

Objective:In order to further enrich and improve the pricing strategy of chronic disease health management services in China.Methods:A discrete choice test was used to investigate the willingness to pay for personalized health service packages for chronic disease patients in Wuhou District,Chengdu City,as a representative of personalized health service packages for primary healthcare institutions,with integration as a utility indicator and blood pressure/glucose control rate as an effect indicator,which was used as a basis for pricing.Results:A total of 238 valid questionnaires were considered.According to conditional logit regression analysis,respondents were willing to pay 147.13 yuan/year to improve service package integration from low to high,and 177.12 yuan/year to improve blood pressure/blood sugar from one day a week(low level)to seven days a week(high level),but there was no significant willingness to pay for other improvements.Conclusion:It is discovered that there is a comparable willingness to pay for health management services to patients with chronic diseases in Chinese community in terms of service utility and effect,and it is proposed that the value of service experience be included in primary health management pricing.

Objective:To explore the difficulties and methods of value-based pricing of healthcare services,and to provide references for the price management of healthcare services in China.Methods:Based on the analysis of literature and policy,the operational methods of value-based pricing are clarified,and the international application experience of value-based pricing is reviewed.Comprehensive field research and interviews are conducted to analyze the difficulties in applying value-based pricing to healthcare services.Results:Currently,there are no mature theories and methods for value-based pricing of healthcare services,and there are also many practical difficulties in financing,payment,assessment and evaluation policies.Conclusion:In the future,it should consider incorporating service experience into the value framework independently of utility,and take"service utility"as the basis for pricing healthcare services,and select relevant indicators for measurement.At the same time,the price of healthcare services should take into account the willingness to pay of multiple parties,and stakeholders need to work closely together to form a consensus on value.

Objective:Compared to pricing based on input value,pricing based on output can better motivate service outcomes towards expectations and enhance input-output efficiency.The path of outcome value-oriented pricing for healthcare services is explored to provide a theoretical foundation for the value-based pricing of healthcare services.Methods:The concepts,methods and international experience of value pricing are sorted out.Results:Outcome-based pricing in healthcare services is divided into effect and utility,and is classified into four categories based on the different emphasis on the effect and utility of healthcare services.Conclusion:Services with a strong emphasis on effectiveness can draw inspiration from the Quantified Quality of Life(QALY)results in the medical technology field,while services with a strong emphasis on utility may require the development of new utility scales for service evaluation.

Objective:In order to further enrich and improve the pricing strategy of chronic disease health management services in China.Methods:A discrete choice test was used to investigate the willingness to pay for personalized health service packages for chronic disease patients in Wuhou District,Chengdu City,as a representative of personalized health service packages for primary healthcare institutions,with integration as a utility indicator and blood pressure/glucose control rate as an effect indicator,which was used as a basis for pricing.Results:A total of 238 valid questionnaires were considered.According to conditional logit regression analysis,respondents were willing to pay 147.13 yuan/year to improve service package integration from low to high,and 177.12 yuan/year to improve blood pressure/blood sugar from one day a week(low level)to seven days a week(high level),but there was no significant willingness to pay for other improvements.Conclusion:It is discovered that there is a comparable willingness to pay for health management services to patients with chronic diseases in Chinese community in terms of service utility and effect,and it is proposed that the value of service experience be included in primary health management pricing.

Objective:To explore the difficulties and methods of value-based pricing of healthcare services,and to provide references for the price management of healthcare services in China.Methods:Based on the analysis of literature and policy,the operational methods of value-based pricing are clarified,and the international application experience of value-based pricing is reviewed.Comprehensive field research and interviews are conducted to analyze the difficulties in applying value-based pricing to healthcare services.Results:Currently,there are no mature theories and methods for value-based pricing of healthcare services,and there are also many practical difficulties in financing,payment,assessment and evaluation policies.Conclusion:In the future,it should consider incorporating service experience into the value framework independently of utility,and take"service utility"as the basis for pricing healthcare services,and select relevant indicators for measurement.At the same time,the price of healthcare services should take into account the willingness to pay of multiple parties,and stakeholders need to work closely together to form a consensus on value.